Bodei Lisa, Hofland Leo J, Ferone Diego, Mooy Cornelia M, Kros Johan M, Paridaens Dion A, Baarsma Seerp G, Ferdeghini Marco, Van Hagen Martin P, Krenning Eric P, Kwekkeboom Dik J
Department of Nuclear Medicine, Erasmus University Medical Centre, Rotterdam, The Netherlands.
Cancer Biother Radiopharm. 2003 Dec;18(6):895-902. doi: 10.1089/108497803322702860.
Scintigraphy with radiolabeled benzamides was used in melanoma patients. Studies with a newer benzamide called 123I-epidepride, a high-affinity D2 receptor (D2R) antagonist, showed high sensitivity in D2R-positive pituitary adenomas. We evaluated the presence of D2R in patients with uveal melanomas in vivo with 123I-epidepride, and in vitro in melanomas, using immunohistochemistry (IHC) and 125I-epidepride autoradiography. We studied the in vivo tumor-to-background (TB) ratios in six patients with posterior uveal melanoma (one previously enucleated). IHC was performed in 3 of 6 tumors after enucleation and in another 20 uveal melanomas, 7 metastatic lymph nodes from skin melanoma, and 2 normal specimens. 125I-epidepride autoradiography was performed in 10 uveal melanomas (3 of which were studied in vivo), 7 metastases, and 2 normal samples. Radioligand uptake was present in the affected eye of 5 patients with uveal melanoma (TB = 3.1-6.1) and absent in the operated one (TB = 1). Eight uveal tumors were positive at IHC (35%), 14 weakly positive (61%), and 1 negative (4%). Two metastases were positive (29%), 2 weakly positive (29%), and 3 negative (42%). Two uveal tumors were positive at autoradiography (20%), 7 had nonspecific binding (70%), and 1 was negative (10%). One metastasis was positive (14%), while 6 were negative (86%). 123I-epidepride scintigraphy in uveal melanomas seems promising for sensitivity and image quality. D2R was demonstrated in a significant proportion of the melanomas, although 123I-epidepride uptake might also be nonspecific and unrelated to D2R binding. Although further studies on larger series are needed, 123I-epidepride could represent a future tool to study the expression of D2R in other classes of neuroendocrine tumors.
放射性标记的苯甲酰胺闪烁扫描术被应用于黑色素瘤患者。对一种名为123I-表阿朴吗啡的新型苯甲酰胺（一种高亲和力的D2受体拮抗剂）进行的研究表明，其对D2R阳性垂体腺瘤具有高敏感性。我们使用123I-表阿朴吗啡在体内评估葡萄膜黑色素瘤患者体内D2R的存在情况，并通过免疫组织化学（IHC）和125I-表阿朴吗啡放射自显影术在体外对黑色素瘤进行评估。我们研究了6例后葡萄膜黑色素瘤患者（其中1例先前已摘除眼球）体内的肿瘤与本底（TB）比值。在6例肿瘤中的3例摘除眼球后进行了免疫组织化学检测，另外还对20例葡萄膜黑色素瘤、7例皮肤黑色素瘤转移淋巴结以及2例正常标本进行了检测。对10例葡萄膜黑色素瘤（其中3例在体内进行了研究）、7例转移灶以及2例正常样本进行了125I-表阿朴吗啡放射自显影术检测。葡萄膜黑色素瘤患者中，5例患者患眼存在放射性配体摄取（TB = 3.1 - 6.1），而手术摘除眼则无摄取（TB = 1）。8例葡萄膜肿瘤免疫组织化学检测呈阳性（35%），14例弱阳性（61%），1例阴性（4%）。2例转移灶呈阳性（29%），2例弱阳性（29%），3例阴性（42%）。2例葡萄膜肿瘤放射自显影术检测呈阳性（20%），7例有非特异性结合（70%），1例阴性（10%）。1例转移灶呈阳性（14%），6例阴性（86%）。123I-表阿朴吗啡闪烁扫描术在葡萄膜黑色素瘤的敏感性和图像质量方面似乎很有前景。在相当一部分黑色素瘤中证实存在D2R，尽管123I-表阿朴吗啡摄取也可能是非特异性的，且与D2R结合无关。尽管需要对更大样本量进行进一步研究，但123I-表阿朴吗啡可能成为未来研究其他类型神经内分泌肿瘤中D2R表达的一种工具。
